Bringing together treatment and referral advice from existing guidelines, this text aims to improve access to services and recognition of common mental health disorders in adults and provide advice on the principles that need to be adopted to develop appropriate referral and local care pathways.

The introduction of antipsychotic agents in the 1950’s substantially improved the treatment of schizophrenia and other psychotic disorders. However, clinical and functional outcomes are still far less than optimal for patients, and have not improved in recent years despite the development of several new antipsychotics. Efficacy rates are further compromised by medication non-adherence, which has been reported to affect more than half of patients. In response to these issues, several non-pharmacological interventions have been developed for the treatment of schizophrenia, such as cognitive behavioral therapy, cognitive remediation, social cognition training and metacognitive approaches. Although these interventions have produced promising results, there is still much controversy regarding their usefulness and applicability in clinical practice. A major impeding factor for their dissemination is possibly a lack of sufficient evidence regarding their specific indications, mechanisms of action, adverse effects, but also practical issues concerning the interpretability of respective clinical studies, such as the choice of outcome variables and control of confounding factors. The present Research Topic includes original research articles and reviews addressing these issues.

One of the side effects of the COVID-19 pandemic was the worsening of the symptomatology of mental disorders. The number of people with mental disorders has increased and pre-existing mental disorders have worsened, in many cases. Psychopharmacology alone is not sufficient for the treatment of conditions such as schizophrenia, depression, bipolar disorder, and generalized anxiety disorder, among others, and the combined use of psychopharmacology and non-pharmacological interventions is recommended by international guidelines. Despite this, most people around the world do not have access to non-pharmacological interventions and when they are diagnosed with a mental disorder, only psychopharmacological drugs are prescribed. In other cases, although non-pharmacological interventions, for example psychotherapy, are also prescribed, this response takes a long time.

This authoritative, clinically relevant resource offers state-of-the-art discussions on the current status of geriatric psychopharmacology-furnishing an empirically based approach to the treatment of psychiatric disorders in elderly patients and focusing on the management of specific illnesses. Examines the pharmacological treatment of depression in conjunction with other conditions, including heart disease, cancer, Parkinson's disease, and dementia! Written by more than 20 internationally recognized experts representing distinguished institutions in the United States and Europe, Geriatric Psychopharmacology reviews the pharmacokinetics of psychotropic drugs and neurochemistry during the aging process analyzes therapeutic approaches to psychotic depression, major depression, and bereavement-related depression describes anticonvulsant and lithium therapy for bipolar disorder and lithium toxicity in older patients details the treatment of late-life psychosis and psychosis in Parkinson's disease explains therapeutic approaches for anxiety, panic, and obsessive-compulsive disorder as well as the role of sedative-hypnotics addresses the neuroleptic and nonneuroleptic treatment of dementia and more!

This title sets out clear recommendations for healthcare staff, based on the best available evidence, on how to diagnose and manage both children and adults who have ADHD to significantly improve their treatment and care.

Dementia, now known as major neurocognitive disorder, is not one monolithic disease. Nor is behavior disturbance driven by one particular neurocognitive dysfunction. In fact if we are able to understand it, behavior is an excellent form of nonverbal communication. There are many different causes of dementia. A major challenge with both researching and implementing interventions is viewing dementia and related behaviors as single entities. This approach leaves room for critical errors in the treatment of dementia patients, beginning with misdiagnosis. This book approaches dementia by reviewing cognitive and functional assessments to provide a more accurate diagnosis, which then allows physicians to design specific interventions that are tailored to the person and their challenges. Because person centered care is vital to quality of life and longevity to an aging patient, this understanding of individual needs is vital. Written by experts in the field, this book incorporates the latest evidence-based behavioral interventions matched to specific deficits. Behavioral management focuses not on controlling behavior, but using it to teach staff and caregivers how to interpret common actions and maximize function for people with major neurocognitive disorders. Quality of life and individualized care planning will be the theme and the book will provide practical case examples. The book begins by introducing dementia and other neurocognitive illnesses, contextualizing them both historically and contemporarily. Next, the text focuses on the comprehensive assessment of a person with neurocognitive challenges in order to identify strengths and understand what the person is trying to communicate with their behavior. This process allows individualized care planning and behavioral (non-pharmacologic) management to meet the cognitive challenges and maximize individual strengths and thereby improve outcomes, making this a cutting edge resource.